trial
as of 2026-07-01Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
NCTId NCT03287778
at a glance
— · Completed
Enrollment 17 (actual)
Sponsored by University of North Carolina, Chapel Hill
Primary completion 2022-12-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-12-01
Primary completion
2022-12-30
Eligibility
ALL · 18 Years · 80 Years
Interventions & indications
Sponsors
University of North Carolina, Chapel HillLead Sponsor
Foundation of Hope, North CarolinaCollaborator
Investigators
1
Lars F. Jarskog, MDPrincipal Investigator
Sites
1 total
Chapel Hill, United States
Facts & assertions
4 sourced
Enrollment
17
Phase
NA
Primary Completion Date
2022-12-30
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person